Immunopharmacological role of the Leukotriene Receptor Antagonists and inhibitors of leukotrienes generating enzymes in Multiple Sclerosis

References

• Kulkarni AP, Kellaway LA, Lahiri DK, Kotwal GJ.Neuroprotection from complement-mediated inflammatory damage. Ann N Y Acad Sci 2004; Dec; 1035:147–64.
   PubMed Web of Science ®Google Scholar
• van d, V De, Groot CJ. Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. Neuropathol Appl Neurobiol 2000; Feb;26(1):2–10.
   PubMedGoogle Scholar
• Nijeholt GJ. Reduction of brain volume in MS. MRI and pathology findings. J Neurol Sci 2005; Jun 15;233(1–2):199–202.
   PubMedGoogle Scholar
• Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006; Aug;129(Pt 8):1953–71.
   PubMedGoogle Scholar
• Andersson A, Karlsson J. Genetics of experimental autoimmune encephalomyelitis in the mouse. Arch Immunol Ther Exp (Warsz) 2004; Sep;52(5):316–25.
   PubMedGoogle Scholar
• Neu I, Mallinger J, Wildfeuer A, Mehlber L. Leukotrienes in the cerebrospinal fluid of multiple sclerosis patients. Acta Neurol Scand 1992; Dec;86(6):586–7.
   PubMedGoogle Scholar
• Neu IS, Metzger G, Zschocke J, Zelezny R, Mayatepek E. Leukotrienes in patients with clinically active multiple sclerosis. Acta Neurol Scand 2002; Jan;105(1):63–6.
   PubMedGoogle Scholar
• Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992;10:153–87.
   PubMed Web of Science ®Google Scholar
• Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 2008; Jul;9(7):516–26.
   PubMedGoogle Scholar
• Pergola C, Dodt G, Rossi A, et al.ERK-mediated regulation of leukotriene biosynthesis by androgens: a molecular basis for gender differences in inflammation and asthma. Proc Natl Acad Sci U S A 2008; Dec 16;105(50):19881–6.
   Google Scholar
• Evangelou N, Jackson M, Beeson D, Palace J. Association of the APOE epsilon4 allele with disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1999; Aug;67(2):203–5.
   PubMedGoogle Scholar
• Haines JL, Ter-Minassian M, Bazyk A, et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat Genet 1996; Aug;13(4):469–71.
   PubMedGoogle Scholar
• Mirshafiey A, Mohsenzadegan M. Antioxidant therapy in multiple sclerosis. Immunopharmacol Immunotoxicol 2009;31(1):13–29.
   PubMedGoogle Scholar
• Myhr KM, Raknes G, Nyland H, Vedeler C. Immunoglobulin G Fc-receptor (FcgammaR) IIA and IIIB polymorphisms related to disability in MS. Neurology 1999; Jun 10;52(9):1771–6.
   Google Scholar
• Sadovnick AD, Dyment D, Ebers GC. Genetic epidemiology of multiple sclerosis. Epidemiol Rev 1997;19(1):99–106.
   PubMedGoogle Scholar
• Fernandez O, Fernandez V, Alonso A, et al. DQB1*0602 allele shows a strong association with multiple sclerosis in patients in Malaga, Spain. J Neurol 2004; Apr;251(4):440–4.
   PubMedGoogle Scholar
• Barcellos LF, Oksenberg JR, Green AJ, et al. Genetic basis for clinical expression in multiple sclerosis. Brain 2002; Jan;125(Pt 1):150–8.
   PubMedGoogle Scholar
• Schmidt H, Williamson D, Ashley-Koch A. HLA-DR15 haplotype and multiple sclerosis: a HuGE review. Am J Epidemiol 2007; May 15;165(10):1097–109.
   Google Scholar
• Sospedra M, Muraro PA, Stefanova I, et al. Redundancy in antigen-presenting function of the HLA-DR and -DQ molecules in the multiple sclerosis-associated HLA-DR2 haplotype. J Immunol 2006; Feb 1;176(3):1951–61.
   PubMedGoogle Scholar
• DeLuca GC, Ramagopalan SV, Herrera BM, et al.An extreme of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Natl Acad Sci U S A 2007; Dec 26;104(52):20896–901.
   PubMedGoogle Scholar
• Hutter C. On the causes of multiple sclerosis. Med Hypotheses 1993; Aug;41(2):93–6.
   PubMedGoogle Scholar
• Hutter CD, Laing P. Multiple sclerosis: sunlight, diet, immunology and aetiology. Med Hypotheses 1996; Feb;46(2):67–74.
   PubMedGoogle Scholar
• Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 2002; Jul;125(Pt 7):1450–61.
   PubMed Web of Science ®Google Scholar
• Gallai V, Sarchielli P, Trequattrini A, et al. Cytokine secretion and eicosanoid production in the peripheral blood mononuclear cells of MS patients undergoing dietary supplementation with n-3 polyunsaturated fatty acids. J Neuroimmunol 1995; Feb;56(2):143–53.
   PubMedGoogle Scholar
• Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002; Dec;21(6):495–505.
   PubMedGoogle Scholar
• Zamaria N. Alteration of polyunsaturated fatty acid status and metabolism in health and disease. Reprod Nutr Dev 2004; May;44(3):273–82.
   PubMedGoogle Scholar
• Alcaro MC, Papini AM. Contribution of peptides to multiple sclerosis research. Biopolymers 2006;84(4):349–67.
   PubMedGoogle Scholar
• Bar-Or A. Human immune studies in multiple sclerosis. Adv Neurol 2006;98:91–109.
   PubMedGoogle Scholar
• Birnbaum G. Making the diagnosis of multiple sclerosis. Adv Neurol 2006;98:111–24.
   PubMedGoogle Scholar
• Goldman MD, Cohen JA, Fox RJ, Bethoux FA. Multiple sclerosis: treating symptoms, and other general medical issues. Cleve Clin J Med 2006; Feb;73(2):177–86.
   PubMedGoogle Scholar
• Mirshafiey A. Venom therapy in multiple sclerosis. Neuropharmacology 2007; Sep;53(3):353–61.
   PubMedGoogle Scholar
• Inglese M. Multiple sclerosis: new insights and trends. AJNR Am J Neuroradiol 2006; May;27(5):954–7.
   PubMedGoogle Scholar
• Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; Jun;47(6):707–17.
   PubMedGoogle Scholar
• Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003; Feb 15;206(2):165–71.
   PubMedGoogle Scholar
• Neumann H, Medana IM, Bauer J, Lassmann H. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 2002; Jun;25(6):313–9.
   PubMedGoogle Scholar
• Redford EJ, Smith KJ, Gregson NA, et al. A combined inhibitor of matrix metalloproteinase activity and tumour necrosis factor-alpha processing attenuates experimental autoimmune neuritis. Brain 1997; Oct;120 ( Pt 10):1895–905.
   PubMedGoogle Scholar
• Babbe H, Roers A, Waisman A, et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000; Aug 7;192(3):393–404.
   PubMedGoogle Scholar
• Jacobsen M, Cepok S, Quak E, et al. Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain 2002; Mar;125(Pt 3):538–50.
   PubMedGoogle Scholar
• Lafaille JJ, Keere FV, Hsu AL, et al. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J Exp Med 1997; Jul 21;186(2):307–12.
   PubMedGoogle Scholar
• Stefferl A, Brehm U, Storch M, et al. Myelin oligodendrocyte glycoprotein induces experimental autoimmune encephalomyelitis in the “resistant” Brown Norway rat: disease susceptibility is determined by MHC and MHC-linked effects on the B cell response. J Immunol 1999; Jul 1;163(1):40–9.
   PubMedGoogle Scholar
• Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007; Apr;8(4):345–50.
   PubMedGoogle Scholar
• Thakker P, Leach MW, Kuang W, Benoit SE, Leonard JP, Marusic S. IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. J Immunol 2007; Feb 15;178(4):2589–98.
   PubMedGoogle Scholar
• Owens T. The enigma of multiple sclerosis: inflammation and neurodegeneration cause heterogeneous dysfunction and damage. Curr Opin Neurol 2003; Jun;16(3):259–65.
   PubMedGoogle Scholar
• Peterson LK, Fujinami RS. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. J Neuroimmunol 2007; Mar;184(1–2):37–44.
   PubMedGoogle Scholar
• Silber E, Sharief MK. Axonal degeneration in the pathogenesis of multiple sclerosis. J Neurol Sci 1999; Nov 15;170(1):11–8.
   PubMedGoogle Scholar
• Constam DB, Philipp J, Malipiero UV, ten DP, Schachner M, Fontana A. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J Immunol 1992; Mar 1;148(5):1404–10.
   PubMedGoogle Scholar
• Huan J, Culbertson N, Spencer L, et al. Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res 2005; Jul 1;81(1):45–52.
   PubMedGoogle Scholar
• Barnstein BO, Li G, Wang Z, et al. Stat5 expression is required for IgE-mediated mast cell function. J Immunol 2006; Sep 1;177(5):3421–6.
   PubMedGoogle Scholar
• Bo L, Vedeler CA, Nyland H, Trapp BD, Mork SJ. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 2003; Aug;9(4):323–31.
   PubMedGoogle Scholar
• Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; Nov;128(Pt 11):2705–12.
   PubMedGoogle Scholar
• Pulizzi A, Rovaris M, Judica E, et al. Determinants of disability in multiple sclerosis at various disease stages: a multiparametric magnetic resonance study. Arch Neurol 2007; Aug;64(8):1163–8.
   PubMedGoogle Scholar
• Sellebjerg F, Jaliashvili I, Christiansen M, Garred P. Intrathecal activation of the complement system and disability in multiple sclerosis. J Neurol Sci 1998; May 7;157(2):168–74.
   PubMedGoogle Scholar
• van HJ, Schreibelt G, Bo L, et al. NAD(P)H:quinone oxidoreductase 1 expression in multiple sclerosis lesions. Free Radic Biol Med 2006; Jul 15;41(2):311–7.
   PubMedGoogle Scholar
• Derwenskus J, Lublin FD. Use of interferon-beta in the treatment of multiple sclerosis. Adv Neurol 2006;98:257–71.
   PubMedGoogle Scholar
• Goodin DS.Treatment of multiple sclerosis with human beta interferon. Int MS J 2005; Nov;12(3):96–108.
   PubMedGoogle Scholar
• Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987; May;50(5):511–6.
   PubMedGoogle Scholar
• Mirshafiey A, Saadat F, Attar M, Di PR, Sedaghat R, Cuzzocrea S. Design of a new line in treatment of experimental rheumatoid arthritis by artesunate. Immunopharmacol Immunotoxicol 2006;28(3):397–410.
   PubMedGoogle Scholar
• Stangel M, Gold R, Gass A, et al. Current issues in immunomodulatory treatment of multiple sclerosis—a practical approach. J Neurol 2006; Feb;253 Suppl 1:I32–I36.
   Google Scholar
• Bailie MB, Standiford TJ, Laichalk LL, Coffey MJ, Strieter R, Peters-Golden M. Leukotriene-deficient mice manifest enhanced lethality from Klebsiella pneumonia in association with decreased alveolar macrophage phagocytic and bactericidal activities. J Immunol 1996; Dec 15;157(12):5221–4.
   PubMedGoogle Scholar
• Benjamin CF, Canetti C, Cunha FQ, Kunkel SL, Peters-Golden M. Opposing and hierarchical roles of leukotrienes in local innate immune versus vascular responses in a model of sepsis. J Immunol 2005; Feb 1;174(3):1616–20.
   PubMedGoogle Scholar
• DeWitt DL. Cox-2-selective inhibitors: the new super aspirins. Mol Pharmacol 1999; Apr;55(4):625–31.
   PubMedGoogle Scholar
• Ferreira SH, Moncada S, Vane JR. Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat New Biol 1971; Jun 23;231(25):237–9.
   PubMedGoogle Scholar
• Gijon MA, Spencer DM, Kaiser AL, Leslie CC. Role of phosphorylation sites and the C2 domain in regulation of cytosolic phospholipase A2. J Cell Biol 1999; Jun 14;145(6):1219–32.
   PubMedGoogle Scholar
• Nalefski EA, Sultzman LA, Martin DM, et al. Delineation of two functionally distinct domains of cytosolic phospholipase A2, a regulatory Ca(2+)-dependent lipid-binding domain and a Ca(2+)-independent catalytic domain. J Biol Chem 1994; Jul 8;269(27):18239–49.
   PubMedGoogle Scholar
• Parente L. Pros and cons of selective inhibition of cyclooxygenase-2 versus dual lipoxygenase/cyclooxygenase inhibition: is two better than one? J Rheumatol 2001; Nov;28(11):2375–82.
   PubMedGoogle Scholar
• Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987; Sep 4;237(4819):1171–6.
   PubMedGoogle Scholar
• Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996; Dec 27;271(52):33157–60.
   PubMedGoogle Scholar
• Dixon RA, Jones RE, Diehl RE, Bennett CD, Kargman S, Rouzer CA.Cloning of the cDNA for human 5-lipoxygenase. Proc Natl Acad Sci U S A 1988; Jan;85(2):416–20.
   PubMedGoogle Scholar
• Matsumoto T, Funk CD, Radmark O, Hoog JO, Jornvall H, Samuelsson B. Molecular cloning and amino acid sequence of human 5-lipoxygenase. Adv Prostaglandin Thromboxane Leukot Res 1989; 19:466–9.
   PubMedGoogle Scholar
• Samuelsson B, Funk CD. Enzymes involved in the biosynthesis of leukotriene B4. J Biol Chem 1989; Nov 25;264(33):19469–72.
   PubMedGoogle Scholar
• Funk CD, Chen XS, Johnson EN, Zhao L. Lipoxygenase genes and their targeted disruption. Prostaglandins Other Lipid Mediat 2002; Aug;68–69:303–12.
   PubMed Web of Science ®Google Scholar
• Kuhn H, Walther M, Kuban RJ. Mammalian arachidonate 15-lipoxygenases structure, function, and biological implications. Prostaglandins Other Lipid Mediat 2002; Aug;68–69:263–90.
   PubMed Web of Science ®Google Scholar
• Michel AA, Steinhilber D, Werz O. Development of a method for expression and purification of the regulatory C2-like domain of human 5-lipoxygenase. Protein Expr Purif 2008; May;59(1):110–6.
   PubMedGoogle Scholar
• Maas RL, Ingram CD, Taber DF, Oates JA, Brash AR. Stereospecific removal of the DR hydrogen atom at the 10-carbon of arachidonic acid in the biosynthesis of leukotriene A4 by human leukocytes. J Biol Chem 1982; Nov 25;257(22):13515–9.
   PubMedGoogle Scholar
• Panossian A, Hamberg M, Samuelsson B. On the mechanism of biosynthesis of leukotrienes and related compounds. FEBS Lett 1982; Dec 27;150(2):511–3.
   PubMedGoogle Scholar
• Radmark O, Malmsten C, Samuelsson B, et al. Leukotriene A: stereochemistry and enzymatic conversion to leukotriene B. Biochem Biophys Res Commun 1980; Feb 12;92(3):954–61.
   PubMedGoogle Scholar
• Shimizu T, Radmark O, Samuelsson B.Enzyme with dual lipoxygenase activities catalyzes leukotriene A4 synthesis from arachidonic acid. Proc Natl Acad Sci U S A 1984; Feb;81(3):689–93.
   PubMedGoogle Scholar
• Abramovitz M, Wong E, Cox ME, Richardson CD, Li C, Vickers PJ. 5-lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. Eur J Biochem 1993; Jul 1;215(1):105–11.
   PubMedGoogle Scholar
• Kargman S, Rousseau P, Reid GK, et al. Leukotriene synthesis in U937 cells expressing recombinant 5-lipoxygenase. J Lipid Mediat 1993; May;7(1):31–45.
   PubMedGoogle Scholar
• Coffey M, Peters-Golden M, Fantone JC III, Sporn PH. Membrane association of active 5-lipoxygenase in resting cells. Evidence for novel regulation of the enzyme in the rat alveolar macrophage. J Biol Chem 1992; Jan 5;267(1):570–6.
   PubMedGoogle Scholar
• Mancini JA, Abramovitz M, Cox ME, et al. 5-lipoxygenase-activating protein is an arachidonate binding protein. FEBS Lett 1993; Mar 8;318(3):277–81.
   PubMedGoogle Scholar
• Woods JW, Coffey MJ, Brock TG, Singer II, Peters-Golden M. 5-Lipoxygenase is located in the euchromatin of the nucleus in resting human alveolar macrophages and translocates to the nuclear envelope upon cell activation. J Clin Invest 1995; May;95(5):2035–46.
   PubMedGoogle Scholar
• Brock TG, Paine R, III, Peters-Golden M. Localization of 5-lipoxygenase to the nucleus of unstimulated rat basophilic leukemia cells. J Biol Chem 1994; Sep 2;269(35):22059–66.
   PubMedGoogle Scholar
• Peters-Golden M, McNish RW. Redistribution of 5-lipoxygenase and cytosolic phospholipase A2 to the nuclear fraction upon macrophage activation. Biochem Biophys Res Commun 1993; Oct 15;196(1):147–53.
   PubMedGoogle Scholar
• Woods JW, Evans JF, Ethier D, et al. 5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. J Exp Med 1993; Dec 1;178(6):1935–46.
   PubMedGoogle Scholar
• Aharony D, Stein RL. Kinetic mechanism of guinea pig neutrophil 5-lipoxygenase. J Biol Chem 1986; Sep 5;261(25):11512–9.
   PubMedGoogle Scholar
• Brideau C, Chan C, Charleson S, et al. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol 1992; Jun;70(6):799–807.
   PubMedGoogle Scholar
• Clark SR, Coffey MJ, Maclean RM, et al. Characterization of nitric oxide consumption pathways by normal, chronic granulomatous disease and myeloperoxidase-deficient human neutrophils. J Immunol 2002; Nov 15;169(10):5889–96.
   PubMedGoogle Scholar
• Furukawa M, Yoshimoto T, Ochi K, Yamamoto S. Studies on arachidonate 5-lipoxygenase of rat basophilic leukemia cells. Biochim Biophys Acta 1984; Oct 4;795(3):458–65.
   PubMedGoogle Scholar
• Hogaboom GK, Cook M, Newton JF, et al. Purification, characterization, and structural properties of a single protein from rat basophilic leukemia (RBL-1) cells possessing 5-lipoxygenase and leukotriene A4 synthetase activities. Mol Pharmacol 1986; Dec;30(6):510–9.
   PubMedGoogle Scholar
• Radmark O. Arachidonate 5-lipoxygenase. Prostaglandins Other Lipid Mediat 2002; Aug;68–69:211–34.
   PubMedGoogle Scholar
• Riendeau D, Falgueyret JP, Guay J, Ueda N, Yamamoto S.Pseudoperoxidase activity of 5-lipoxygenase stimulated by potent benzofuranol and N-hydroxyurea inhibitors of the lipoxygenase reaction. Biochem J 1991; Feb 15;274 ( Pt 1):287–92.
   PubMedGoogle Scholar
• Rouzer CA, Matsumoto T, Samuelsson B.Single protein from human leukocytes possesses 5-lipoxygenase and leukotriene A4 synthase activities. Proc Natl Acad Sci U S A 1986; Feb;83(4):857–61.
   PubMed Web of Science ®Google Scholar
• Chang WC, Nelson C, Parekh AB.Ca2++ influx through CRAC channels activates cytosolic phospholipase A2, leukotriene C4 secretion, and expression of c-fos through ERK-dependent and -independent pathways in mast cells. FASEB J 2006; Nov;20(13):2381–3.
   PubMedGoogle Scholar
• Lin LL, Wartmann M, Lin AY, Knopf JL, Seth A, Davis RJ. cPLA2 is phosphorylated and activated by MAP kinase. Cell 1993; Jan 29;72(2):269–78.
   PubMedGoogle Scholar
• Rosado JA, Sage SO. Role of the ERK pathway in the activation of store-mediated calcium entry in human platelets. J Biol Chem 2001; May 11;276(19):15659–65.
   PubMedGoogle Scholar
• Schonwasser DC, Marais RM, Marshall CJ, Parker PJ. Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol Cell Biol 1998; Feb;18(2):790–8.
   PubMedGoogle Scholar
• Leslie CC. Properties and regulation of cytosolic phospholipase A2. J Biol Chem 1997; Jul 4;272(27):16709–12.
   PubMedGoogle Scholar
• Reynolds LJ, Hughes LL, Louis AI, Kramer RM, Dennis EA. Metal ion and salt effects on the phospholipase A2, lysophospholipase, and transacylase activities of human cytosolic phospholipase A2. Biochim Biophys Acta 1993; Apr 23;1167(3):272–80.
   PubMedGoogle Scholar
• Dai H, Huang W, Xu J, et al. Binding model of human coactosin-like protein with filament actin revealed by mutagenesis. Biochim Biophys Acta 2006; Nov;1764(11):1688–700.
   PubMedGoogle Scholar
• Rakonjac M, Fischer L, Provost P, et al.Coactosin-like protein supports 5-lipoxygenase enzyme activity and up-regulates leukotriene A4 production. Proc Natl Acad Sci U S A 2006; Aug 29;103(35):13150–5.
   PubMedGoogle Scholar
• Lam BK. Leukotriene C4 synthase: a critical enzyme for the biosynthesis of SRS-A. Front Biosci 1997; Jul 15;2:d380–d386.
   Google Scholar
• Lam BK. Leukotriene C(4) synthase. Prostaglandins Leukot Essent Fatty Acids 2003; Aug;69(2–3):111–6.
   PubMedGoogle Scholar
• Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990; Sep 6;323(10):645–55.
   PubMedGoogle Scholar
• Ma KF, Yang HY, Chen Z, Qi LY, Zhu DY, Lou YJ. Enhanced expressions and activations of leukotriene C4 synthesis enzymes in D-galactosamine/lipopolysaccharide-induced rat fulminant hepatic failure model. World J Gastroenterol 2008; May 7;14(17):2748–56.
   PubMedGoogle Scholar
• Penrose JF, Spector J, Lam BK, et al. Purification of human lung leukotriene C4 synthase and preparation of a polyclonal antibody. Am J Respir Crit Care Med 1995; Jul;152(1):283–9.
   PubMedGoogle Scholar
• Penrose JF. LTC4 synthase. Enzymology, biochemistry, and molecular characterization. Clin Rev Allergy Immunol 1999;17(1–2):133–52.
   PubMedGoogle Scholar
• Sjostrom M, Jakobsson PJ, Juremalm M, et al. Human mast cells express two leukotriene C(4) synthase isoenzymes and the CysLT(1) receptor. Biochim Biophys Acta 2002; Jun 13;1583(1):53–62.
   PubMedGoogle Scholar
• Bernstrom K, Orning L, Hammarstrom S. Gamma-Glutamyl transpeptidase, a leukotriene metabolizing enzyme. Methods Enzymol 1982;86:38–45.
   PubMedGoogle Scholar
• Nagaoka I, Yamashita T. Conversion of leukotriene C4 to leukotriene D4 by a cell-surface enzyme of rat macrophages. Biochem Biophys Res Commun 1987; Aug 31;147(1):282–7.
   PubMedGoogle Scholar
• Inamura T, Pardridge WM, Kumagai Y, Black KL. Differential tissue expression of immunoreactive dehydropeptidase I, a peptidyl leukotriene metabolizing enzyme. Prostaglandins Leukot Essent Fatty Acids 1994; Feb;50(2):85–92.
   PubMedGoogle Scholar
• Nagaoka I, Yamashita T. Studies on the leukotriene D4-metabolizing enzyme of rat leukocytes, which catalyzes the conversion of leukotriene D4 to leukotriene E4. Biochim Biophys Acta 1987; Oct 31;922(1):8–17.
   PubMedGoogle Scholar
• Nagaoka I, Yamada M, Kira S, Yamashita T. Comparative studies on the leukotriene D4-metabolizing enzyme of different types of leukocytes. Comp Biochem Physiol B 1988;89(2):375–80.
   PubMedGoogle Scholar
• Raulf M, Konig W, Koller M, Stuning M. Release and functional characterization of the leukotriene D4-metabolizing enzyme (dipeptidase) from human polymorphonuclear leucocytes. Scand J Immunol 1987; Mar;25(3):305–13.
   PubMedGoogle Scholar
• Haeggstrom JZ, Kull F, Rudberg PC, Tholander F, Thunnissen MM. Leukotriene A4 hydrolase. Prostaglandins Other Lipid Mediat 2002; Aug;68–69:495–510.
   PubMedGoogle Scholar
• Amat M, Diaz C, Vila L. Leukotriene A4 hydrolase and leukotriene C4 synthase activities in human chondrocytes: transcellular biosynthesis of Leukotrienes during granulocyte-chondrocyte interaction. Arthritis Rheum 1998; Sep; 41(9):1645–51.
   PubMedGoogle Scholar
• Feinmark SJ, Cannon PJ. Vascular smooth muscle cell leukotriene C4 synthesis: requirement for transcellular leukotriene A4 metabolism. Biochim Biophys Acta 1987; Nov 21;922(2):125–35.
   PubMedGoogle Scholar
• Maclouf J, Antoine C, Henson PM, Murphy RC. Leukotriene C4 formation by transcellular biosynthesis. Ann N Y Acad Sci 1994; Apr 18;714:143–50.
   PubMedGoogle Scholar
• Maclouf J, Sala A, Rossoni G, Berti F, Muller-Peddinghaus R, Folco G. Consequences of transcellular biosynthesis of leukotriene C4 on organ function. Haemostasis 1996; Oct;26 Suppl 4:28–36.
   PubMedGoogle Scholar
• Maclouf JA, Murphy RC. Transcellular metabolism of neutrophil-derived leukotriene A4 by human platelets. A potential cellular source of leukotriene C4. J Biol Chem 1988; Jan 5;263(1):174–81.
   PubMedGoogle Scholar
• Marcus AJ, Broekman MJ, Safier LB, et al. Formation of leukotrienes and other hydroxy acids during platelet-neutrophil interactions in vitro. Biochem Biophys Res Commun 1982; Nov 16;109(1):130–7.
   PubMedGoogle Scholar
• Ciana P, Fumagalli M, Trincavelli ML, et al.The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J 2006; Oct 4;25(19):4615–27.
   PubMedGoogle Scholar
• Lynch KR, O’Neill GP, Liu Q, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999; Jun 24;399(6738):789–93.
   PubMedGoogle Scholar
• Nothacker HP, Wang Z, Zhu Y, Reinscheid RK, Lin SH, Civelli O. Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol Pharmacol 2000; Dec;58(6):1601–8.
   PubMedGoogle Scholar
• Takasaki J, Kamohara M, Matsumoto M, et al. The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT(2) receptor. Biochem Biophys Res Commun 2000; Aug 2;274(2):316–22.
   PubMedGoogle Scholar
• Figueroa DJ, Breyer RM, Defoe SK, et al. Expression of the cysteinyl leukotriene 1; receptor in normal human lung and peripheral blood leukocytes. Am J Respir Crit Care Med 2001; Jan;163(1):226–33.
   PubMedGoogle Scholar
• Hui Y, Funk CD. Cysteinyl leukotriene receptors. Biochem Pharmacol 2002; Dec 1;64(11):1549–57.
   PubMedGoogle Scholar
• Lotzer K, Spanbroek R, Hildner M, et al. Differential leukotriene receptor expression and calcium responses in endothelial cells and macrophages indicate 5-lipoxygenase-dependent circuits of inflammation and atherogenesis. Arterioscler Thromb Vasc Biol 2003; Aug 1;23(8):e32–e36.
   Google Scholar
• Mellor EA, Maekawa A, Austen KF, Boyce JA.Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells. Proc Natl Acad Sci U S A 2001; Jul 3;98(14):7964–9.
   PubMedGoogle Scholar
• Sarau HM, Ames RS, Chambers J, et al. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol 1999; Sep;56(3):657–63.
   PubMedGoogle Scholar
• Nielsen CK, Campbell JI, Ohd JF, et al. A novel localization of the G-protein-coupled CysLT1 receptor in the nucleus of colorectal adenocarcinoma cells. Cancer Res 2005; Feb 1;65(3):732–42.
   PubMedGoogle Scholar
• Heise CE, O’Dowd BF, Figueroa DJ, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 2000; Sep 29;275(39):30531–6.
   PubMedGoogle Scholar
• Sjostrom M, Johansson AS, Schroder O, Qiu H, Palmblad J, Haeggstrom JZ. Dominant expression of the CysLT2 receptor accounts for calcium signaling by cysteinyl leukotrienes in human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol 2003; Aug 1;23(8):e37–e41.
   PubMedGoogle Scholar
• Lecca D, Trincavelli ML, Gelosa P, et al. The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair. PLoS ONE 2008;3(10): e3579.
   PubMedGoogle Scholar
• Communi D, Janssens R, Suarez-Huerta N, Robaye B, Boeynaems JM. Advances in signalling by extracellular nucleotides. the role and transduction mechanisms of P2Y receptors. Cell Signal 2000; Jun;12(6):351–60.
   PubMedGoogle Scholar
• Stucky CL, Medler KA, Molliver DC. The P2Y agonist UTP activates cutaneous afferent fibers. Pain 2004; May;109(1–2):36–44.
   PubMedGoogle Scholar
• Abbracchio MP, Boeynaems JM, Barnard EA, et al. Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family. Trends Pharmacol Sci 2003; Feb;24(2):52–5.
   PubMedGoogle Scholar
• Communi D, Parmentier M, Boeynaems JM. Cloning, functional expression and tissue distribution of the human P2Y6 receptor. Biochem Biophys Res Commun 1996; May 15;222(2):303–8.
   PubMedGoogle Scholar
• Haynes SE, Hollopeter G, Yang G, et al. The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat Neurosci 2006; Dec;9(12):1512–9.
   PubMedGoogle Scholar
• Koizumi S, Shigemoto-Mogami Y, Nasu-Tada K, et al. UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature 2007; Apr 26;446(7139):1091–5.
   PubMedGoogle Scholar
• Korcok J, Raimundo LN, Du X, Sims SM, Dixon SJ. P2Y6 nucleotide receptors activate NF-kappaB and increase survival of osteoclasts. J Biol Chem 2005; Apr 29;280(17):16909–15.
   PubMedGoogle Scholar
• Osipchuk Y, Cahalan M. Cell-to-cell spread of calcium signals mediated by ATP receptors in mast cells. Nature 1992; Sep 17;359(6392):241–4.
   PubMedGoogle Scholar
• Warny M, Aboudola S, Robson SC, et al. P2Y(6) nucleotide receptor mediates monocyte interleukin-8 production in response to UDP or lipopolysaccharide. J Biol Chem 2001; Jul 13;276(28):26051–6.
   PubMedGoogle Scholar
• Back M, Bu DX, Branstrom R, Sheikine Y, Yan ZQ, Hansson GK.Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci U S A 2005; Nov 29;102(48):17501–6.
   PubMedGoogle Scholar
• Lundeen KA, Sun B, Karlsson L, Fourie AM. Leukotriene B4 receptors BLT1 and BLT2: expression and function in human and murine mast cells. J Immunol 2006; Sep 1;177(5):3439–47.
   PubMed Web of Science ®Google Scholar
• Nicolete R, Rius C, Piqueras L, et al. Leukotriene B4-loaded microspheres: a new therapeutic strategy to modulate cell activation. BMC Immunol 2008; Jul 15;9:36.
   PubMedGoogle Scholar
• Qiu H, Johansson AS, Sjostrom M, et al.Differential induction of BLT receptor expression on human endothelial cells by lipopolysaccharide, cytokines, and leukotriene B4. Proc Natl Acad Sci U S A 2006; May 2;103(18):6913–8.
   PubMedGoogle Scholar
• Subbarao K, Jala VR, Mathis S, et al. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol 2004; Feb;24(2):369–75.
   PubMedGoogle Scholar
• Tager AM, Bromley SK, Medoff BD, et al. Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat Immunol 2003; Oct;4(10):982–90.
   PubMedGoogle Scholar
• Toda A, Yokomizo T, Shimizu T. Leukotriene B4 receptors. Prostaglandins Other Lipid Mediat 2002; Aug;68–69:575–85.
   PubMedGoogle Scholar
• Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPAR alpha-leukotriene B4 pathway to inflammation control. Nature 1996; Nov 7;384(6604):39–43.
   PubMedGoogle Scholar
• Peres CM, Aronoff DM, Serezani CH, Flamand N, Faccioli LH, Peters-Golden M. Specific leukotriene receptors couple to distinct G proteins to effect stimulation of alveolar macrophage host defense functions. J Immunol 2007; Oct 15;179(8):5454–61.
   PubMedGoogle Scholar
• Jiang Y, Borrelli LA, Kanaoka Y, Bacskai BJ, Boyce JA. CysLT2 receptors interact with CysLT1 receptors and down-modulate cysteinyl leukotriene dependent mitogenic responses of mast cells. Blood 2007; Nov 1;110(9):3263–70.
   PubMedGoogle Scholar
• Drazen JM, Israel E, O’Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; Jan 21;340(3):197–206.
   PubMedGoogle Scholar
• Drazen JM, Austen KF. Leukotrienes and airway responses. Am Rev Respir Dis 1987; Oct;136(4):985–98.
   PubMedGoogle Scholar
• Moos MP, Mewburn JD, Kan FW, et al.Cysteinyl leukotriene 2 receptor-mediated vascular permeability via transendothelial vesicle transport. FASEB J 2008; Dec;22(12):4352–62.
   PubMedGoogle Scholar
• Ito Y, Hirano M, Umemoto N, et al. Guinea pig cysteinyl leukotriene receptor 2 (gpCysLT2) mediates cell proliferation and intracellular calcium mobilization by LTC4 and LTD4. BMB Rep 2008 Feb 29;41(2):139–45.
   PubMedGoogle Scholar
• Woszczek G, Chen LY, Nagineni S, et al. IFN-gamma induces cysteinyl leukotriene receptor 2 expression and enhances the responsiveness of human endothelial cells to cysteinyl leukotrienes. J Immunol 2007 Apr 15;178(8):5262–70.
   PubMedGoogle Scholar
• Simmons PM, Salmon JA, Moncada S. The release of leukotriene B4 during experimental inflammation. Biochem Pharmacol 1983; Apr 15;32(8):1353–9.
   PubMedGoogle Scholar
• Mancuso P, Nana-Sinkam P, Peters-Golden M. Leukotriene B4 augments neutrophil phagocytosis of Klebsiella pneumoniae. Infect Immun 2001; Apr;69(4):2011–6.
   PubMedGoogle Scholar
• Peres CM, de Paula L, Medeiros AI, Sorgi CA, Soares EG, Carlos D, Peters-Golden M, Faccioli LH. Inhibition of leukotriene biosynthesis abrogates the host control of Mycobacterium tuberculosis. Microbes Infect 2007; Apr;9(4):483–9.
   PubMedGoogle Scholar
• Vaddi K, Newton RC. Regulation of monocyte integrin expression by beta-family chemokines. J Immunol 1994; Nov 15;153(10):4721–32.
   PubMedGoogle Scholar
• Flamand L, Tremblay MJ, Borgeat P. Leukotriene B4 triggers the in vitro and in vivo release of potent antimicrobial agents. J Immunol 2007; Jun 15;178(12):8036–45.
   PubMedGoogle Scholar
• Wan M, Sabirsh A, Wetterholm A, Agerberth B, Haeggstrom JZ.Leukotriene B4 triggers release of the cathelicidin LL-37 from human neutrophils: novel lipid-peptide interactions in innate immune responses. FASEB J 2007; Sep;21(11):2897–905.
   PubMedGoogle Scholar
• Rosnowska M, Cendrowski W, Sobczyk W. [Leukotrienes B4 and C4 in cerebrospinal of patients with multiple sclerosis]. Pol Merkur Lekarski 1997; Apr;2(10):254–5.
   PubMedGoogle Scholar
• Whitney LW, Ludwin SK, McFarland HF, Biddison WE. Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions. J Neuroimmunol 2001; Dec 3;121(1–2):40–8.
   PubMedGoogle Scholar
• Uz T, Dimitrijevic N, Tueting P, Manev H. 5-lipoxygenase (5LOX)-deficient mice express reduced anxiety-like behavior. Restor Neurol Neurosci 2002;20(1–2):15–20.
   PubMedGoogle Scholar
• Barnes NC, de JB, Miyamoto T. Worldwide clinical experience with the first marketed leukotriene receptor antagonist. Chest 1997; Feb;111(2 Suppl):52S–60S.
   Google Scholar
• Dempsey OJ.Leukotriene receptor antagonist therapy. Postgrad Med J 2000; Dec;76(902):767–73.
   PubMedGoogle Scholar
• Kuperman AV, Kalgutkar AS, Marfat A, Chambers RJ, Liston TE. Pharmacokinetics and metabolism of a cysteinyl leukotriene-1 receptor antagonist from the heterocyclic chromanol series in rats: in vitro-in vivo correlation, gender-related differences, isoform identification, and comparison with metabolism in human hepatic tissue. Drug Metab Dispos 2001; Nov;29(11):1403–9.
   PubMedGoogle Scholar
• McDanel DL, Muller BA. The linkage between Churg-Strauss syndrome and leukotriene receptor antagonists: fact or fiction? Ther Clin Risk Manag 2005; Jun;1(2):125–40.
   PubMedGoogle Scholar
• Okudaira H. Challenge studies of a leukotriene receptor antagonist. Chest 1997; Feb;111(2 Suppl):46S–51S.
   Google Scholar
• Rodger IW. From bench to bedside. The hurdles of discovering a new leukotriene receptor antagonist. Am J Respir Crit Care Med 2000; Feb; 161(2 Pt 2):S7–S10.
   PubMedGoogle Scholar
• Marusic S, Thakker P, Pelker JW, et al. Blockade of cytosolic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses. J Neuroimmunol 2008; Nov 15;204(1–2):29–37.
   PubMedGoogle Scholar
• Payne SG, Oskeritzian CA, Griffiths R, et al. The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. Blood 2007; Feb 1;109(3):1077–85.
   PubMedGoogle Scholar
• Kirkland TA, Adler M, Bauman JG, et al. Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem 2008; May 1;16(9):4963–83.
   PubMedGoogle Scholar
• Prosiegel M, Neu I, Vogl S, Hoffmann G, Wildfeuer A, Ruhenstroth-Bauer G. Suppression of experimental autoimmune encephalomyelitis by sulfasalazine. Acta Neurol Scand 1990; Mar;81(3):237–8.
   PubMedGoogle Scholar
• Fretland DJ, Widomski DL, Shone RL, Levin S, Gaginella TS. Effect of the leukotriene B4 receptor antagonist, SC-41930, on experimental allergic encephalomyelitis (EAE) in the guinea pig. Agents Actions 1991; Sep; 34(1–2):172–4.
   PubMedGoogle Scholar
• Gladue RP, Carroll LA, Milici AJ, et al. Inhibition of leukotriene B4-receptor interaction suppresses eosinophil infiltration and disease pathology in a murine model of experimental allergic encephalomyelitis. J Exp Med 1996; Apr 1;183(4):1893–8.
   PubMedGoogle Scholar
• Liston TE, Conklyn MJ, Houser J, et al. Pharmacokinetics and pharmacodynamics of the leukotriene B4 receptor antagonist CP-105,696 in man following single oral administration. Br J Clin Pharmacol 1998; Feb; 45(2):115–21.
   PubMedGoogle Scholar
• Marder P, Spaethe SM, Froelich LL, et al. Inhibition of ex vivo neutrophil activation by oral LY293111, a novel leukotriene B4 receptor antagonist. Br J Clin Pharmacol 1996; Oct; 42(4):457–64.
   Google Scholar
• Showell HJ, Conklyn MJ, Alpert R, et al. The preclinical pharmacological profile of the potent and selective leukotriene B4 antagonist CP-195543. J Pharmacol Exp Ther 1998; Jun; 285(3):946–54.
   PubMedGoogle Scholar
• Birke FW, Meade CJ, Anderskewitz R, Speck GA, Jennewein HM. In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B(4) receptor antagonist. J Pharmacol Exp Ther 2001; Apr; 297(1):458–66.
   PubMedGoogle Scholar
• Emerson MR, LeVine SM. Experimental allergic encephalomyelitis is exacerbated in mice deficient for 12/15-lipoxygenase or 5-lipoxygenase. Brain Res 2004; Sep 17;1021(1):140–5.
   PubMedGoogle Scholar